For sufferers with kind 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is related to a decrease danger for venous thromboembolism (VTE), in accordance with a research scheduled for presentation on the annual assembly of the American Society of Hematology, to be held from Dec. 7 to 10 in San Diego.
Cho Han Chiang, M.D., from Mount Auburn Hospital in Cambridge, Massachusetts, and colleagues examined whether or not GLP-1 RA use would cut back the danger for VTE amongst sufferers with T2DM in a retrospective, propensity score-matched multicenter database evaluation. Sufferers who obtained GLP-1 RAs had been in comparison with those that obtained dipeptidyl peptidase-4 (DPP-4) inhibitors; after propensity rating matching, the ultimate evaluation included two cohorts of 168,428 sufferers every.
The researchers discovered that the incidence of VTE was 11.0 versus 12.9 occasions per 1,000 patient-years within the GLP-1 RA and DPP-4 inhibitor cohorts, respectively, with an 18% decrease danger for VTE for these receiving GLP-1 RAs (hazard ratio [HR], 0.82). In contrast with these on DPP-4 inhibitors, sufferers receiving GLP-1 RAs had a decrease danger for pulmonary embolism and deep venous thrombosis (HRs, 0.78 and 0.85, respectively). In a subgroup evaluation, the variations in VTE charges had been related for sufferers with and with out weight problems (HRs, 0.80 and 0.82, respectively).
“These results support the hypothesis that use of GLP-1 RA can lead to a reduction in VTE risk,” the authors write. “Further studies are needed to elucidate the mechanisms and causality underlying the association between GLP-1 RA use and reduction of VTE risk, and whether these findings extend to patients using GLP-1 RA for weight control without T2DM.”
Extra info:
AbstractMore Info
2024 HealthDay. All rights reserved.
Quotation:
GLP-1 RA use tied to decrease charge of venous thromboembolism in diabetes (2024, November 14)
retrieved 14 November 2024
from https://medicalxpress.com/information/2024-11-glp-ra-venous-thromboembolism-diabetes.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
